Sara C Meyer

List of Publications by Year
in descending order

25 papers	1,012 citations	687363 13 h-index	610901 24 g-index
25 all docs	25 docs citations	25 times ranked	1952 citing authors

#	Article	IF	Citations
1	JAK2 in Myeloproliferative Neoplasms: Still a Protagonist. Pharmaceuticals, 2022, 15, 160.	3.8	11
2	Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia. Current Oncology, 2022, 29, 805-815.	2.2	3
3	Genetics of Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2021, 35, 217-236.	2.2	13
4	Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 1013-1020.	2.8	10
5	Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Hamostaseologie, 2021, 41, 197-205.	1.9	2
6	Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. Leukemia, 2021, 35, 2875-2884.	7.2	19
7	Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms. HemaSphere, 2021, 5, e516.	2.7	24
8	Recent Advances in Molecular Diagnostics and Targeted Therapy of Myeloproliferative Neoplasms. Cancers, 2021, 13, 5035.	3.7	1
9	MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages. Blood, 2020, 136, 2591-2595.	1.4	12
10	Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. Journal of Clinical Investigation, 2019, 129, 1596-1611.	8.2	84
11	Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. Cancer Cell, 2018, 33, 44-59.e8.	16.8	71
12	Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2017, 31, 627-642.	2.2	32
13	Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance. Haematologica, 2017, 102, 1650-1660.	3.5	49
14	Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation. EBioMedicine, 2017, 26, 112-125.	6.1	35
15	In response to the comment by Hechler et al .: Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.. Haematologica, 2017, 102, e504-e505.	3.5	2
16	Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. BioMed Research International, 2017, 2017, 1-13.	1.9	7
17	Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. Journal of Experimental Medicine, 2016, 213, 1479-1496.	8.5	101
18	JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. Blood, 2016, 128, 839-851.	1.4	35

#	Article	IF	Citations
19	CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell, 2015, 28, 15-28.	16.8	124
20	Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncology, The, 2014, 15, e382-e394.	10.7	106
21	Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors. Clinical Cancer Research, 2014, 20, 2051-2059.	7.0	140
22	Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors. Cell Reports, 2013, 5, 1047-1059.	6.4	116
23	Severe cutaneous toxicity related to Eltrombopag. British Journal of Haematology, 2013, 160, 412-414.	2.5	13
24	Addition of Omega-3 Î±-Linolenic Acid to Platelet Apheresis Units Preserves Platelet Activatability Over Time and Reduces Baseline Activation Under Routine Storage Conditions: A Pilot Study. Blood, 2012, 120, 3433-3433.	1.4	2
25	Prognostic Impact of Iron Overload During Follow-up After Allogeneic Stem Cell Transplantation. Blood, 2011, 118, 347-347.	1.4	0